14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VOR vs NKTR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
VOR Captures Overall Composite Edge (57.8 HOLD vs 61.1 BUY), While NKTR Leads 3–2 on Growth & Valuation Pillars
VOR Overall Winner
6-Pillar Tally: VOR 2 – 3 NKTR (1 Tie)
Matrix Metrics: VOR 4 – 5 NKTR
As of Nov 16, 2026, Vor Biopharma Inc. (VOR) captures the overall head-to-head institutional edge over Nektar Therapeutics (NKTR) on higher Unified Composite conviction (57.8/100 HOLD vs. 61.1/100 BUY) after splitting the core matrix 4–5 (led by Balance Sheet & Cash Flow, Options & Positioning), while NKTR wins 3–2 across the 6-pillar growth and valuation breakdown. VOR trades at $18.97 (N/M Forward P/E, 0.0% operating margin) versus NKTR at $36.44 (34.0x Forward P/E, -303.6% operating margin).
Composite vs. Pillar Nuance: While NKTR currently prints a higher short-term Unified Composite Score (61.1/100 BUY vs. VOR 57.8/100 HOLD), VOR captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -303.6% operating margin) and revenue trajectory (+0.0% vs. -20.4% YoY).
Technical & Structure Timing Caution: VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4); meanwhile NKTR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VOR vs NKTR. Trailing 12-month operating profitability (VOR 0.0% vs NKTR -303.6%) and valuation multiples (VOR N/M vs NKTR 34.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.3B market capitalization and -303.6% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ VOR vs NKTR Key Questions & Quantitative Answers
As of Nov 16, 2026, Vor Biopharma Inc. (VOR) captures the overall head-to-head institutional edge over Nektar Therapeutics (NKTR) on higher Unified Composite conviction (57.8/100 HOLD vs. 61.1/100 BUY) after splitting the core matrix 4–5 (led by Balance Sheet & Cash Flow, Options & Positioning), while NKTR wins 3–2 across the 6-pillar growth and valuation breakdown. VOR trades at $18.97 (N/M Forward P/E, 0.0% operating margin) versus NKTR at $36.44 (34.0x Forward P/E, -303.6% operating margin). Composite vs. Pillar Nuance: While NKTR currently prints a higher short-term Unified Composite Score (61.1/100 BUY vs. VOR 57.8/100 HOLD), VOR captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -303.6% operating margin) and revenue trajectory (+0.0% vs. -20.4% YoY). Technical & Structure Timing Caution: VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4); meanwhile NKTR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NKTR leads the Growth & Scale pillar: VOR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NKTR at -20.4% YoY revenue growth and +0.0% YoY earnings growth on $52M TTM revenue (100.0% gross margin, -303.6% operating margin). On trailing 12-month operating scale, VOR generates N/A in USD-normalized revenue versus $52M for NKTR. In operating R&D and SG&A reinvestment, VOR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NKTR.
NKTR screens cheaper on headline valuation multiples. VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas NKTR trades at 34.0x Forward P/E, 34.0x Trailing P/E, 0.31x PEG, and 25.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VOR (-125.4% ROE) versus NKTR (-37.9% ROE) capital efficiency.
In options market volatility and institutional positioning, VOR carries 120.2% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.90β · 61% Vol realized risk). By comparison, NKTR carries 109.0% implied volatility (11th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.09β · 47% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.